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Background: The RHD gene is highly polymorphic, which results in a large number of RhD
variant phenotypes. Discrepancies in RhD typing are still a problem in blood banks and
increase the risk of alloimmunization. In this study, the RhD typing strategy at a blood bank
in  Brazil was evaluated.
Methods: One-hundred and ﬁfty-two samples typed as RhD negative and C or E positive by
routine tests (automated system and indirect antiglobulin test using the tube technique)
were reevaluated for RhD status by three methods. The method with the best performance
was  implemented and evaluated for a period of one year (n = 4897 samples). Samples that
were D positive exclusively in the conﬁrmatory test were submitted to molecular analysis.
Results: The gel test for indirect antiglobulin testing with anti-D immunoglobulin G (clone
ESD1)  presented the best results. Seventy samples (1.43%) previously typed as RhD negative
showed reactivity in the gel test for indirect antiglobulin testing and were reclassiﬁed as D
positive. D variants that may cause alloimmunization, such as weak D type 2 and partial
DVI, were detected.
Conclusion: The conﬁrmatory RhD test using the gel test for indirect antiglobulin testing
represents a breakthrough in transfusion safety in this blood center. Our results emphasize
the  importance of assessing the blood group typing strategy in blood banks.©  2015 Associac¸ão Brasileira de Hematologia, Hemoterapia e Terapia Celular. Published
transfusion reactions and hemolytic diseases of the fetus and
newborns.1 Despite methodological advances, discrepanciesIntroductionThe D blood group antigen is the most clinically important
protein of the Rh system due to its involvement in hemolytic
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in Rh typing are still a problem during routine immunohema-
tology service tests.2–4
 e Terapia Celular. Published by Elsevier Editora Ltda. All rights
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The RHD gene is highly polymorphic as it has more  than
00 alleles. This results in a large number of RhD variant
henotypes.5 Rh discrepancies may arise when an individual
as a variant of the D antigen, such as partial D or weak D, and
ay be mistyped as D negative. These discrepancies can cause
ncorrect blood component transfusions, leading to increased
isk of alloimmunization.3
In addition to the great number of variants, a major cause
f discrepancies in RhD typing is the existence of several RhD
yping methods and reagents with different sensitivities.6–9
lood group typing strategies and policies for the selection
f methods and reagents vary between countries.2 In addi-
ion, few centers in the world routinely perform molecular
ests for the Rh typing of blood donors. Therefore, despite
he best efforts, the number of D variant blood donors typed
s D negative, even by an indirect antiglobulin test (IAT),
s greater than previously expected.10 This misclassiﬁcation
esults in an increased risk of anti-D alloimmunization, which
as important health implications, especially for women of
hildbearing age.
In this study, the effectiveness of serological tests used for
he RhD typing of blood donors were evaluated in a large blood
enter in Brazil (Fundac¸ão Hemominas).
ethods
tudy  population
n the ﬁrst step of this study, red blood cell (RBC) samples from
52 blood donors phenotyped as D negative who were C or E
ositive in routine tests using an automated system (Olympus
K72000) were analyzed. These samples were tested for weak
 by three different serological methods and using different
eagents.
The second step consisted of implementing and evalu-
ting a protocol of RhD phenotyping based on an indirect
ntiglobulin technique using LISS/Coombs gel cards (Diamed,
witzerland) and a monoclonal reagent, anti-D immunoglob-
lin G (IgG) (clone ESD1). This conﬁrmatory test was evaluated
nd compared to the IAT tube test over one year to verify
he RhD status of blood donors (n = 4897) who were pheno-
yped as D negative and C or E positive or with extended
henotyping.
The last step of this study consisted of using molecular
ethods to conﬁrm the RhD status of the samples that were
yped as D positive exclusively in the conﬁrmatory gel test for
ndirect antiglobulin testing (n = 39).
erological  studies
hD typing was ﬁrst performed with an automated system
Olympus PK 7200) using two anti-D reagents: a monoclonal
lend of anti-D clones (MS  201 and MS  26; Fresenius Kabi,
razil) diluted 1–32 and 1–64 in saline solution, and a mono-
lonal antibody blend of RUM-1 and MS-26 clones (Lorne
eagents) diluted 1–64 in saline solution. All donor RBCs were
reated with 0.2% bromelin. RBCs found to be D negative were
urther tested for weak D by IAT (tube technique) using a
onoclonal anti-D blend (Fresenius Kabi, Brazil). 1 5;3  7(5):302–305 303
All D negative RBC samples were tested with monoclonal
antisera (anti-CDE), and clones P3X61, P3X25513G8 and P3X234
(Fresenius Kabi, Brazil) in a tube, according to the manufac-
turer’s instructions.
The samples typed as D negative and C or E positive, as
described above, were tested for weak D (IAT) using three
protocols: anti-D blend clones MS-26 and TH-28 (Diamed,
Switzerland) in a tube; anti-D blend clones MS-26 and TH-
28 in gel cards; and the anti-D IgG clone ESD1 in gel
cards. The gel tests were performed on cards (ID LISS
Coombs; Diamed, Switzerland) and were incubated at 37 ◦C for
15 min.
The protocol for weak D using anti-D ESD1 in gel cards was
implemented in the blood center as a routine conﬁrmatory
test and was evaluated for one year.
Molecular  analyses
Samples typed as D positive in the conﬁrmatory test were
submitted to multiplex polymerase chain reaction (PCR) to
amplify ﬁve RHD-speciﬁc exons: 3, 4, 5, 7 and 9.11,12 The sam-
ples were also analyzed for the presence of weak D Types 1,
2 and 3 using a PCR-sequence speciﬁc primer (PCR-SSP)13 and
were tested for the presence of other D variants using RHD
BeadChipTM analysis (BioArray Solutions, Immucor) according
to the manufacturer’s instructions.
Ethical  considerations
The Ethics Committee of the Fundac¸ão Hemominas approved
the study (CEP no.136.163).
Results
Samples from 152 blood donors typed as D negative and C or
E positive by an automated system were evaluated using the
three protocols. Nine (5.9%) of the samples phenotyped as D
negative by the tube test presented positive results in gel cards
(LISS/Coombs) using anti-D IgG (clone ESD1). The anti-D blend
reagent (clones MS-26 and TH-28) detected positivity of eight
of these samples. The D positive status of the nine samples
was conﬁrmed by RHD genotyping.
Based on these results, Fundac¸ão Hemominas decided to
implement a protocol to conﬁrm RhD typing using anti-D IgG
monoclonal (clone ESD1) in gel cards of all blood donors phe-
notyped as D negative and C or E positive or with extended
phenotyping.
During one year, 4897 samples of blood donors from dif-
ferent regions of Minas Gerais (Brazil) were referred to this
blood center to conﬁrm the RhD typing. All RBC samples had
originally been tested with an anti-D blend (clones MS-26 and
TH-28; Diamed-Biorad) by the tube test.
The results of this study showed that 70 samples (1.43%)
previously typed as RhD negative by the tube test presented
weak reactivity in gel cards using anti-D IgG (clone ESD1) and
were reclassiﬁed as D positive.
In the subsequent step of this study, RHD genotyping was
performed of 39 samples typed as D negative by the tube
test that were weakly positive in the conﬁrmatory gel test.
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152 samples RhD
neg CDE pos
8 samples reclassified
as RhD positive
9 samples reclassified
as RhD positive
70 samples reclassified
as RhD positive
RHD*DVI (n=2)
RHD*weak D type 1 (n=3)
RHD*weak D type 2 (n=8)
RHD*weak D type 3 (n=1)
RHD*DAR (n=1)
RHD/RHD*DIIIa-CE(4-7)-D (n=1)
RHD*DAR/DIIIa-CE(4-7)-D (n=2)
RHD*weak D type 2/DIIIa-CE(4-7)-D (n=1)
No RHD variant detected (n=20)
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4897 samples RhD neg
CDE pos or with extended
phenotyping
39 samples RhD
positive exclusively in
confirmatory IAT gel
Molecular analyses:
RHD multiplex PCR
PCR-SSP
RHD BeadChipTM
Confirmatory test for weak D
(IAT) using anti-D monoclonal
IgG clone ESD1 in gel cards
anti-D blend clones MS-26
and TH-28 in a tube
anti-D blend clones MS-26
and TH-28 in gel cards
anti-D monoclonal IgG
clone ESD1 in gel cards
lar cFigure 1 – Flowchart for the serological and molecu
Twenty-seven of these 39 samples ampliﬁed all of the RHD-
speciﬁc exons by multiplex PCR, and twelve samples failed
to amplify at least one RHD exon. The samples were further
assessed by PCR-SSP and RHD BeadChipTM analysis and were
characterized as follows: RHD*DVI (n = 2), RHD*weak D type 1
(n = 3), RHD*weak D type 2 (n = 8), RHD*weak D type 3 (n = 1),
RHD*DAR (n = 1), heterozygous RHD/RHD*DIIIa-CE(4-7)-D (n = 1),
RHD*DAR/DIIIa-CE(4-7)-D (n = 2) and RHD*weak D type 2/DIIIa-
CE(4-7)-D (n = 1). In twenty samples, RHD variants were not
detected by RHD BeadChip analysis.
Figure 1 summarizes the results.
Discussion
The correct determination of the RhD phenotype is of great
importance in transfusion medicine. The existence of a large
number of polymorphisms of the RHD gene and the plethora
of variant RhD phenotypes, coupled with the availability of a
large number of methods and reagents, makes RhD pheno-
typing a challenge.3
To evaluate RhD phenotyping in Fundac¸ão Hemominas,
three different methods were compared to conﬁrm weak D
tests (IAT) of samples from 152 Brazilian blood donors. Gel
cards presented the best results to detect anti-D IgG (clone
ESD1); this technique could be used as a conﬁrmatory test.
This method was implemented in the blood Center and eval-
uated over the course of one year with 4897 blood donors.
During this period, 1.43% (n = 70) of the samples previously
typed as D negative by the tube test presented positive results
exclusively in the gel test for indirect antiglobulin testing, and
were reclassiﬁed as D positive.onﬁrmatory RhD tests performed for blood donors.
The molecular tests used to conﬁrm the RhD status of 39
samples typed as D negative by IAT and as weak D positive in
the conﬁrmatory gel test revealed the presence of D variants
[RHD*DVI, RHD*weak D type 1, RHD*weak D type 2, RHD*weak D
type 3, RHD*DAR,  the heterozygous RHD/RHD*DIIIa-CE(4-7)-D,
RHD*DAR/DIIIa-CE(4-7)-D and RHD*weak D type 2/DIIIa-CE(4-7)-
D)] in 19 samples (48.7%). Weak D type 2 is among the most
prevalent D variants in Brazil.9 While weak D type 2 presents
a relatively low antigenic density, it is expected to react in a
tube or in gel without an antiglobulin test.14 However, some
studies show that weak D type 2 and DVI, as well as some other
D variants, may not react with some anti-D reagents in a direct
test and may react very weakly in the tube test.9 Therefore,
these samples may occasionally be mistyped as D negative in
routine tests.4,9,15
There are many  factors that can affect the reproducibility
and reliability of the tube test. These factors include prob-
lems in the washing step, variability in individual reading
techniques and the level of expertise needed to accurately
grade results.16 All of these factors, coupled with the variable
reactivity displayed by some anti-D reagents with D variant
samples and the heterogeneous ethnic composition of Brazil-
ian blood donors which can generate a complex scenario of
RhD variants, may explain the results obtained herein.9,17
Interestingly, no RhD variant was detected by RHD Bead-
Chip for twenty of the 39 samples (51.3%). However, the
ampliﬁcation of all of the RHD exons evaluated and the posi-
tivity of the conﬁrmatory serologic tests indicate that these are
RhD positive samples. This result can be explained by the fact
that the RHD BeadChip kit detects approximately 80 variants
while there are currently hundreds of known RhD variants.
Moreover, a recent study described a high prevalence of the
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18. Costa S, Martin F, Chiba A, Langhi D Jr, Chiattone C, Bordin J.
RHD alleles and D antigen density among serologicallyrev bras hematol hemot
HD gene in Brazilian samples phenotyped as C or E posi-
ive with a very low density of the D antigen, mainly weak
 type 38, and indicates the need for the implementation of
HD molecular screening in serologically D negative and C or E
ositive Brazilian donors to reduce the risk of D immunization
ssociated with the erroneous transfusion of weak D RBCs to
 negative recipients.18
onclusion
he implementation of the conﬁrmatory RhD test using the
el test for indirect antiglobulin testing for RhD negative and
DE positive samples in the blood center represents a break-
hrough in transfusion safety thereby allowing the correct RhD
yping of dozens of samples that would have been erroneously
lassiﬁed as D negative by direct automated RhD phenotyping
ollowed by the tube test. Moreover, this strategy demonstrates
he technical feasibility, even in a large blood center such
s the Fundac¸ão Hemominas, which types 270,000 samples
or ABO/RhD and approximately 37,700 IAT tests for weak D
nnually.
These results emphasize the importance of assessing the
lood group typing strategy in blood banks. This evaluation is
mportant because RhD typing discrepancies can occur even
ith the use of standard techniques and reagents that the
anufacturers claim are effective for detecting weak D vari-
nts. Thus, each center must evaluate which protocol is best
uited to local conditions. In addition, RHD genotyping again
roved to be a very useful tool in identifying inconclusive RhD
yping cases.
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